RTTNews BiotechDoubao · 实盘不做把握 6/10不做原因:已被定价
北京时间·🕒 发布 21:08:40·⟳ 抓取 21:15:17 +6m37s·⚡ 决策 10-12 21:17:38 +2m21s·15.0 天前
Mirum 的 LIVMARLI 三期 EXPAND 达主要终点（胆道闭锁等超罕见胆汁淤积性肝病），拟2027H1递交sNDA，但盘前冲高14%后已回落至平盘附近
真实的阳性三期读出，但读出时点公司10/11已提前预告、10/9股价已提前涨5.73%；盘前消息后一度冲至$98(+13.9%)又在薄量中回落到$86.50(+0.57%)，初始重定价被完全回吐，呈典型利好兑现结构；且为已上市药物的标签扩展、sNDA 2027H1才提交、收入最早2028年兑现，对当前$660-680M收入指引无近期增量。开盘追多风险收益差，阳性数据又不构成做空催化（禁止以sell-the-news开空），故不做。
📄 原文RTTNews Biotech↗ 原文
Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study
Business Business Latest Headlines Top Stories Breaking News Earnings Biotech Investors Stock Alerts IPOs M&A Canadian…
不做 Mirum Pharmaceuticals（MIRM.US）
预期内阳性读出：公司10/11已预告、10/9抢跑+5.73%，盘前冲$98(+13.9%)后在薄量中回落至$86.50(+0.57%)，见光死结构明确；且为已上市药物标签扩展、sNDA 2027H1才提交、收入2028年后，对$660-680M现收入指引无近期弹性，开盘追多风险收益差。数据阳性不构成做空催化（不以sell-the-news开空），故双向不做；若开盘后放量站稳$90上方且电话会给出超预期商业/监管细节，再另行评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
LIVMARLI三期EXPAND达主要终点是实质利好，但读出在预期内（提前预告电话会、周五已涨5.7%），盘前冲高14%后回落至平盘显示市场认为增量有限；sNDA要到2027H1、收入2028年以后，近期无业绩弹性，不追多、也无做空依据。
消息传播链
- 公司10/11预告10/12 8:30 ET召开投资者电话会公布EXPAND顶线结果，读出时点提前一天公开，市场有充分时间布局
- 官方通稿宣布三期EXPAND达主要终点，计划2027H1递交sNDA市场反应:盘前一度冲高至$98（较$86.01收盘+13.9%），至09:15 ET回落至$86.50（+0.57%），盘前量约5,988股
- RTTNews转载并给出盘前报价（其文中$88.50/+2.90%为更早一刻报价，此后进一步回落）
关键理由
- 数据本身扎实：瘙痒(p=0.0004)与胆汁酸(p<0.0001)双终点高度显著、胆道闭锁亚组成立、无新安全信号，标签扩展到胆道闭锁（患者数大于现有ALGS/PFIC适应症）打开中长期空间
- 但该利好已被预期并完成首轮定价：10/11公司预告电话会→10/9抢跑+5.73%→盘前冲$98(+13.9%)后回落至$86.50(+0.57%)，冲高回落本身说明市场不认为有超预期增量
主要风险
- 盘前成交量仅约6千股、买卖价差较宽(bid$86/ask$88.5)，$86.5的回落可能是薄量失真；若开盘后放量站稳$90以上且电话会给出强商业指引，不排除重新走强（即踏空风险）
- 完整数据若在应答者持续性、胆道闭锁全人群或监管要求额外试验上暴露瑕疵，回吐可能延续；样本仅52人
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-11 · 影响 weakens
读出已提前预告、周五抢跑，盘前+14%冲高回落至+0.6%，市场用真实价格投了'增量有限'票，削弱做多edge
检索:Mirum MIRM EXPAND readout pre-announced investor call October 11 sell the news 原文 ↗ - 做多前查反向 · 来源 kb_search · 影响 weakens
行情显示20日累计-12.4%、距60日高-28.7%，13周轨迹持续下行（100→73），中期处于下降通道；本次利好的收入兑现远（2028+），难以仅凭远期标签扩展扭转趋势
检索:MIRM stock down trend September 2026 biliary atresia sNDA timing 2027
先例如何影响了这次决策
对本次决策的影响:自身盘前冲高回落+提前抢跑直接支持AVOID，不依赖外部先例；若强行开盘买入等于承接盘前已消退的买盘
方向:未能在本轮建立经首发锚定校验的同类先例面板（孤儿药IBAT抑制剂标签扩展三期读出样本稀缺），不据此假设涨幅
涨幅量级:不以缺失先例编造tp/sl；幅度判断直接采用标的自身实时盘前价格发现
形态:最直接的'先例'就是本标的自己的盘前路径：利好公布后+13.9%→+0.6%的冲高回落，是预期内临床读出见光死的实时证据，比外部类比更对齐
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`mirm expand study topline results cholestatic pruritus snda 2027 | mirum pharmaceuticals livmarli maralixibat phase 3 expand biliary atresia primary endpoint`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证 - fetch_decision_experience 成功 stock_tools_inprocess · 2 ms
{ - stock_quote 成功 stock_tools HTTP · 3,149 ms
{ - web_search 成功 doubao_search · 1,846 ms
豆包搜索结果（原始查询:Mirum Pharmaceuticals EXPAND Phase 3 LIVMARLI maralixibat biliary atresia topline results press release；API SearchType:web） - web_search 成功 doubao_search · 2,142 ms
豆包搜索结果（原始查询:Mirum MIRM stock LIVMARLI EXPAND readout analyst reaction biliary atresia market opportunity；API SearchType:web）
原文全文
展开原文 · 7,596 字
Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Quick Facts
Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study
By
RTTNews Staff Writer
✉
Published:
10/12/2026 9:08 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Mirum Pharmaceuticals (
MIRM
) announced positive topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for cholestatic pruritus in patients aged six months and older with ultra-rare cholestatic liver diseases, including biliary atresia.
The study enrolled 52 patients who received maralixibat or placebo during a 20-week double-blind period. In pediatric patients, maralixibat improved itch severity by 1.81 points compared with 0.83 points for placebo, achieving a statistically significant treatment difference of 0.98 points (p=0.0004).
Maralixibat also reduced serum bile acids by 70.1% from baseline, compared with 3.5% for placebo, representing a 69% treatment effect (p<0.0001). In patients with biliary atresia and a native liver, the treatment also significantly improved itch severity (p=0.0002).
Safety findings were consistent with previous clinical experience, with no new safety signals observed.
Mirum plans to submit a supplemental New Drug Application to the U.S. FDA in the first half of 2027 based on the EXPAND results. LIVMARLI is already approved for cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis.
The stock closed Friday's trading at $86.01, up 5.73%. In the premarket trading, shares are up 2.90% at $88.50.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Next Story
Latest Updates on Middle East War
Sen. Murphy Says Hegseth Covering Up Cost And Damages Of Iran War
October 09, 2026 07:35 ET
Crude Oil Prices Moderately Higher After Yesterday's Spike
October 09, 2026 14:44 ET
U.S. Stocks Close Mostly Lower On Spike In Oil Prices, OpenAI Revenue Concerns
October 08, 2026 16:17 ET
U.S. Stocks Mostly Lower As Crude Oil Prices Spike
October 08, 2026 11:19 ET
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
View More
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the priva
October 09, 2026 15:35 ET
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
View More Videos
RELATED NEWS
Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study
Mirum's Brelovitug Meets Phase 3 Goals In Chronic Hepatitis Delta Study
Mirum To Announce Topline Results From Phase 3 AZURE-1 Study For Brelovitug
Mirum : FDA Approves Atebrioz For Rare Bone Disorder FOP In Patients Aged 12 And Older
Latest Updates on COVID-19
View More
Most Read
Most Emailed
Alimentation Couche-Tard To Buy Irving Oil Retail Assets In Québec, Ontario
October 09, 2026 10:19 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
Verizon, AT&T And T-Mobile Shares Plunge As SpaceX Strikes Spectrum Deal To Expand Starlink Mobile
October 09, 2026 17:32 ET
Nvidia-backed Australian AI Firm Firmus Scraps IPO Over Market Conditions
October 09, 2026 07:54 ET
Crescent Energy To Buy Devon's Eagle Ford Assets For $3.85 Bln; Launches $1 Bln Stock Offering
October 08, 2026 07:53 ET
DCC Energy Agrees To Sell Nexora To One Equity Partners For $725 Mln
October 09, 2026 02:30 ET
Hexagon To Buy Rocscience For $535 Mln
October 09, 2026 02:46 ET
Starbucks Explores Takeover Of Chipotle In Potential Record Restaurant Deal
October 08, 2026 17:01 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
Microchip Technology Acquires VORAGO Technologies For Undisclosed Sum
October 09, 2026 09:14 ET
Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDA
October 09, 2026 08:17 ET
Netflix Reportedly Plans To Lay Off 5% Of Its Workforce
October 09, 2026 11:17 ET
LG Electronics Q3 Prelim. Operating Income, Revenues Rise; Stock Drops
October 07, 2026 00:57 ET
Teva Pharmaceutical Stock Rises 6% After FDA Approves Monthly Schizophrenia Treatment
October 09, 2026 11:24 ET
Waystream Group Q3 Sales Increase
October 07, 2026 01:14 ET
Alignment Healthcare Stock Falls 17% On 2027 Medicare Star Ratings
October 09, 2026 11:26 ET
Intact Financial Projects Total Pre-tax Catastrophe Losses Of About C$660 Mln In Q3
October 07, 2026 01:15 ET
Toro Slips To Loss In Q2, Shares Down By Over 14%
October 09, 2026 12:02 ET
Ballard Secures 4.8MW Order From Siemens Mobility To Power Romanian Hydrogen Trains
October 07, 2026 01:39 ET
VEON's Banglalink Launches Starlink Satellite-to-mobile In Bangladesh
October 09, 2026 12:12 ET
Lunnon Metals Notes BHP Deal To Sell Kambalda Nickel Concentrator To Gold Fields
October 07, 2026 01:43 ET
Avient Stock Falls 5% After Appointing Mike Frank As CEO
October 09, 2026 12:33 ET
Netcall PLC Profit Falls In Full Year
October 07, 2026 02:09 ET
Editors Pick
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Loading...
Business
Business
Latest Headlines
Top Stories
Breaking News
Earnings
Biotech
Investors
Stock Alerts
IPOs
M&A
Canadian
UK
Wallstreet Events
Industry News
Industry News
Technology
Software
Banking
Automotive
Energy
More
Corp. Calendars
Dividends
Stock Splits
Buybacks
Conference Calls
Earnings Calendar
Earnings Calendar
Pos Pre-announcements
Profit Warnings
Positive Surprise
Negative Surprise
Latest Earnings
FDA Calendars
Drug Approvals
Clinical Trial Calendar
Ratings Changes
Upgrades
Downgrades
Cov Initiations
Cov. Reiterated
Economy
Economic News
US
Europe
Asia
Global
Economic Calendar
Economic Scorecard
Cryptocurrency
Crypto
Cryptocurrency
Blockchain
Markets
Markets
Morning Mkt Analysis
US Commentary
European Commentary
Asian Commentary
Canadian Commentary
Indian Commentary
Commodities
Bonds
Currencies
Politics
Politics
US
World
White House
Elections
General News
Forex
Forex
FX Top Stories
Currency Analysis
Currency Alerts
Economic Calendar
Economic Scorecard
Health
Health
Coronavirus
COVID-19 Calendar
Diet & Fitness
Cannabis
Kids Health
Men's Health
Women's Health
Cancer News
Drug Development
Mental Health
Slide Shows
Entertainment
Entertainment
Top Stories
Music news
Pop
Rock
Classic Rock
Rap/Hip-Hop
Country
Alternative
Oldies
All Genre
Content Licensing
Content Licensing
Newswires & Feeds
Content Syndication
Digital Signage Services
Radio News Services
Premium Services
Premium
Intelligent Investor
Biotech Investor
NEW
Login
More
Latest News Videos
Free Content
RSS Feeds
Press Releases
Search
Contact Us
Quick Facts
Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study
By
RTTNews Staff Writer
✉
Published:
10/12/2026 9:08 AM ET
Follow Us
Join Us
Add
as your preferred news source on Google
Add Now
Mirum Pharmaceuticals (
MIRM
) announced positive topline results from the Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) for cholestatic pruritus in patients aged six months and older with ultra-rare cholestatic liver diseases, including biliary atresia.
The study enrolled 52 patients who received maralixibat or placebo during a 20-week double-blind period. In pediatric patients, maralixibat improved itch severity by 1.81 points compared with 0.83 points for placebo, achieving a statistically significant treatment difference of 0.98 points (p=0.0004).
Maralixibat also reduced serum bile acids by 70.1% from baseline, compared with 3.5% for placebo, representing a 69% treatment effect (p<0.0001). In patients with biliary atresia and a native liver, the treatment also significantly improved itch severity (p=0.0002).
Safety findings were consistent with previous clinical experience, with no new safety signals observed.
Mirum plans to submit a supplemental New Drug Application to the U.S. FDA in the first half of 2027 based on the EXPAND results. LIVMARLI is already approved for cholestatic pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis.
The stock closed Friday's trading at $86.01, up 5.73%. In the premarket trading, shares are up 2.90% at $88.50.
For comments and feedback contact: editorial@rttnews.com
Business News
Slide Shows
Biotech Stocks Facing FDA Decision In October 2026
Biotech Stocks Facing FDA Decision In September 2026
Biotech Stocks Facing FDA Decision In August 2026
Next Story
Latest Updates on Middle East War
Sen. Murphy Says Hegseth Covering Up Cost And Damages Of Iran War
October 09, 2026 07:35 ET
Crude Oil Prices Moderately Higher After Yesterday's Spike
October 09, 2026 14:44 ET
U.S. Stocks Close Mostly Lower On Spike In Oil Prices, OpenAI Revenue Concerns
October 08, 2026 16:17 ET
U.S. Stocks Mostly Lower As Crude Oil Prices Spike
October 08, 2026 11:19 ET
Renewed Spike In Crude Oil Prices May Weigh On Wall Street
October 08, 2026 08:50 ET
View More
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the priva
October 09, 2026 15:35 ET
The minutes of the latest Federal Reserve policy session was the highlight this week which saw relatively less news on the economics front in the U.S. Latest trade data and survey results on the private sector also gained attention. In Europe, results of the purchasing managers’ survey were in focus, while the Reserve Bank of India policy announcement took the center stage in Asia.
View More Videos
RELATED NEWS
Mirum Pharmaceuticals Meets Primary Endpoint In Phase 3 LIVMARLI Study
Mirum's Brelovitug Meets Phase 3 Goals In Chronic Hepatitis Delta Study
Mirum To Announce Topline Results From Phase 3 AZURE-1 Study For Brelovitug
Mirum : FDA Approves Atebrioz For Rare Bone Disorder FOP In Patients Aged 12 And Older
Latest Updates on COVID-19
View More
Most Read
Most Emailed
Alimentation Couche-Tard To Buy Irving Oil Retail Assets In Québec, Ontario
October 09, 2026 10:19 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
Verizon, AT&T And T-Mobile Shares Plunge As SpaceX Strikes Spectrum Deal To Expand Starlink Mobile
October 09, 2026 17:32 ET
Nvidia-backed Australian AI Firm Firmus Scraps IPO Over Market Conditions
October 09, 2026 07:54 ET
Crescent Energy To Buy Devon's Eagle Ford Assets For $3.85 Bln; Launches $1 Bln Stock Offering
October 08, 2026 07:53 ET
DCC Energy Agrees To Sell Nexora To One Equity Partners For $725 Mln
October 09, 2026 02:30 ET
Hexagon To Buy Rocscience For $535 Mln
October 09, 2026 02:46 ET
Starbucks Explores Takeover Of Chipotle In Potential Record Restaurant Deal
October 08, 2026 17:01 ET
Fairfax Financial To Partner With Wittington To Acquire Boots Group
October 07, 2026 09:49 ET
Microchip Technology Acquires VORAGO Technologies For Undisclosed Sum
October 09, 2026 09:14 ET
Natera's Multi-cancer Early Detection Assay Granted Breakthrough Device Designation By FDA
October 09, 2026 08:17 ET
Netflix Reportedly Plans To Lay Off 5% Of Its Workforce
October 09, 2026 11:17 ET
LG Electronics Q3 Prelim. Operating Income, Revenues Rise; Stock Drops
October 07, 2026 00:57 ET
Teva Pharmaceutical Stock Rises 6% After FDA Approves Monthly Schizophrenia Treatment
October 09, 2026 11:24 ET
Waystream Group Q3 Sales Increase
October 07, 2026 01:14 ET
Alignment Healthcare Stock Falls 17% On 2027 Medicare Star Ratings
October 09, 2026 11:26 ET
Intact Financial Projects Total Pre-tax Catastrophe Losses Of About C$660 Mln In Q3
October 07, 2026 01:15 ET
Toro Slips To Loss In Q2, Shares Down By Over 14%
October 09, 2026 12:02 ET
Ballard Secures 4.8MW Order From Siemens Mobility To Power Romanian Hydrogen Trains
October 07, 2026 01:39 ET
VEON's Banglalink Launches Starlink Satellite-to-mobile In Bangladesh
October 09, 2026 12:12 ET
Lunnon Metals Notes BHP Deal To Sell Kambalda Nickel Concentrator To Gold Fields
October 07, 2026 01:43 ET
Avient Stock Falls 5% After Appointing Mike Frank As CEO
October 09, 2026 12:33 ET
Netcall PLC Profit Falls In Full Year
October 07, 2026 02:09 ET
Editors Pick
Delta Stock Drops On Cautious Earnings View In Q4 & FY26 After Weak Q3
October 09, 2026 09:40 ET
PepsiCo Q3 Profit Climbs, Core Margin Down; Updates FY26 View; Stock Gains
October 08, 2026 08:12 ET
Tesco Plc Stock Gains On H1 Profit Growth, FY27 Outlook Upgrade, Addl. Buyback
October 08, 2026 05:39 ET
Walmart Recalls Over 4.4 Mln Grill Brushes For Ingestion Risk
October 02, 2026 09:11 ET
Loading...
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
17bd569ce0· 2026-10-12 21:17 · doubao / doubao-seed-evolving-latest-version · 策略包2226518bfdee当前